Search / Trial NCT00001885

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Nov 3, 1999

Trial Information

Current as of December 26, 2024

Completed

Keywords

Interstitial Lung Disease Inherited Disease Genetic Markers Alpha 1 Protease Inhibitor Dna Mutations Rheumatoid Arthritis Pulmonary Fibrosis Normal Volunteer

ClinConnect Summary

Pulmonary fibrosis that develops within a subpopulation of patients with rheumatoid arthritis is a disorder of unknown etiology. Although previous reports suggest that some individuals with rheumatoid arthritis have a genetic predisposition to the development of fibrotic lung disease, genetic factors have not been clearly identified. It is the intent of this clinical protocol to identify genetic polymorphisms in individuals with pulmonary fibrosis and rheumatoid arthritis.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • Individuals 21 years of age or older with any of the following:
  • RA (based on 1987 American College of Rheumatology Revised Criteria for the Classification of RA) with PF (biopsy-proven), or
  • RA-only, or
  • Biopsy-proven idiopathic PF-only, or
  • Healthy research volunteers.
  • EXCLUSION CRITERIA:
  • Individuals with any of the following:
  • Inhalational exposure to fibrogenic fibers or dusts (e.g., asbestos, silica, coal, beryllium).
  • Chronic pulmonary disorders other than pulmonary fibrosis.
  • Other collagen vascular disorders (e.g., systemic lupus erythematosus, scleroderma, polymyositis, mixed connective tissue disease).
  • Non-rheumatoid arthritis.
  • Viral infections associated with PF (e.g., hepatitis B, hepatitis C, human immunodeficiency virus).
  • Pregnancy.

About National Heart, Lung, And Blood Institute (Nhlbi)

The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials